Quantcast
Channel: Formulary Journal - Jill Wechsler
Browsing all 76 articles
Browse latest View live
↧

Global health challenges spur development of vaccines at home and abroad

It's flu season again, which always focuses public attention on the reliablity and availability of the nation's vaccine supply.

View Article


Drug shortages challenge the healthcare community, FDA, and pharmaceutical...

The outcry from physicians, pharmacists, and patients over disruptions in supplies of vital medicines to treat cancer, pain, and other serious conditions is drawing attention from the White House,...

View Article


FDA promotes innovation, access to medicines while modernizing operations

FDA is under pressure to encourage medical product development, monitor an increasingly global supply chain, and accomplish everything with ever-tighter resources. In the last few years, Congress added...

View Article

High Court to rule on health reform legality

The US Supreme Court, as expected, will decide if key provisions of the Obama administration's healthcare overhaul law violate the Constitution by exceeding the federal government's power to regulate...

View Article

Budget crunch, political battles shape 2012 policy agenda

Election-year politics will color a range of legislative and policy developments affecting drug development, production, and reimbursement in the coming year, as efforts to reduce government spending...

View Article


Health reform promises expanded drug coverage through ACOs, exchanges,...

Last month, economists in the Department of Health and Human Services (HHS) reported a big slow-down in healthcare spending for 2010. Outlays rose only 3.9% to $2.6 trillion, largely because the...

View Article

FDA user fee renewal addresses drug shortages, new drug development

Every 5 years, Congress is called on to reauthorize a series of user fees that support FDA oversight of drugs and medical products. The Prescription Drug User Fee Act (PDUFA) and similar measures...

View Article

FDA unveils guidance for biosimilar development

After months of anticipation, FDA issued guidances last month that outlines its recommendations for developing and approving biosimilar therapies.

View Article


Drug abuse, counterfeits, and critical shortages illustrate need for secure...

The United States is caught in an epidemic of prescription drug overuse and abuse, and efforts to counter such activity are affecting drug distribution, prescribing, and oversight. Just as troubling is...

View Article


FDA user fee legislation heads toward finish line

Legislation to reauthorize FDA user fee programs sailed through the House and Senate last month, setting the stage for leading legislators to resolve their differences and agree on a compromise...

View Article

New models support comparative research, more nonprescription drugs

The drive for personalized medicine and greater patient involvement in treatment decisions demands more informative data on the effects and risks associated with drugs and medical products.

View Article

Health reform survives

In a complex decision, a slim majority of the Supreme Court upheld the constitutionality of the Affordable Care Act.

View Article

Payers seek more comparative research documenting value and affordability of...

While scientists and biomedical researchers at the recent meeting of the American Society of Clinical Oncology (ASCO) applauded encouraging data on dozens of breakthrough cancer therapies, analysts...

View Article


CER studies will shape coverage decisions

To reduce the money spent on treatments that don't work, health plans and payers are examining closely how Comparative Effectiveness Research (CER) can steer patients and providers to more appropriate...

View Article

FDA user fee legislation speeds drug approvals, addresses shortages,...

The passage of the FDA Safety and Innovation Act will support innovation, answer the current shortages, and even regulate mobile applications.

View Article


Medicare Part D plans control drug spending

The Medicare Part D prescription drug program has emerged as the poster child for how private plans can control costs while providing quality care. Even critics of health insurers acknowledge that the...

View Article
Browsing all 76 articles
Browse latest View live